Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Needham analyst N. Quinn Bolton upgraded Marvell (MRVL) to Buy from Hold, with a $21 price target, following the company's inaugural analyst day, in which management laid out its strategy to grow revenue, further streamline operations and increase capital returns to shareholders. 2. Raymond James analyst Simon Leopold upgraded Finisar (FNSR) to Strong Buy from Outperform citing the 23% selloff in shares on Friday. The analyst believes the company's execution issues are "either misunderstood or exaggerated." He sees upside to estimates and has a $40 price target for the shares. 3. Morgan Stanley analyst Rajeev Lalwani upgraded Rockwell Collins (COL) to Overweight from Equal Weight and raised his price target for the shares to $121 from $94. 4. Citi analyst Michael Rollins upgraded Equinix (EQIX) to Buy from Neutral citing prospects for faster growth from the company's European portfolio as well as acquisitions. The analyst raised his price target for the shares to $435. 5. Goldman Sachs analyst Terence Flynn upgraded Blueprint Medicines (BPMC) to Buy from Neutral citing pipeline momentum following last year's data readouts. The analyst expects a "steady flow" of readouts at conferences this year from the extension phases of trials and clarity on potential registration paths. He upped his price target for the shares to $52 from $35. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.